ClinicalTrials.gg
CompletedNCT01431508Updated May 22, 2024Results posted

A Study of Safety and Efficacy in MK-0954A Combination in Participants With Hypertension (MK-0954A-373 AM3)

A Phase 4 interventional study of Losartan 50 mg / HCTZ 12.5 mg in Hypertension, sponsored by Organon and Co. Completed. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-05-22.

Sponsored by Organon and Co · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 1 month after the study started (first participant enrolled Aug 2007, registered Sep 2011).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
15
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 65 studies testing losartan in Hypertension — 5 open to participants now, 5 under way, 1 of them phase 3. Losartan · Hypertension.

Enrollment
57th of 65
15 · median 100
Started
2007
with 2 others
Phase 4
26 of 65
2 open now
Registered
37th of 65
by date
Lead sponsor
7 of 65
Organon and Co

Among the 65 studies testing losartan in Hypertension, this one is the 57th largest by enrollment, is one of 3 that started in 2007, is one of 26 in phase 4, and was the 37th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.

Browse Hypertension studies →

Open to participants now

5 of the 65 studies testing losartan in Hypertension are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About losartan

Losartan: first FDA approval 1995 (COZAAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies testing losartan in Hypertension, or all of them as a file.
02

Study summary

This study is being conducted to evaluate the safety and antihypertensive efficacy of MK-0954A (Losartan 50 mg / Hydrochlorothiazide (HCTZ) 12.5 mg) in participants with mild to moderate essential hypertension.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Hypertension
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant will have reached the legal age by the time of entrance into the run-in period.
  • Participant has no active medical problem, other than essential hypertension,

which might of itself or by this treatment significantly affect the Participant's blood pressure.

  • Participants diagnosed with mild to moderate essential hypertension or

hypertension accompanying with established cardiovascular (CV) and renal diseases who are receiving antihypertensive regimen (exclude diuretic), yet not attaining to treatment goal*.

* Note: For essential hypertension, the goal is to reduce the blood pressure to less than 140/90. For hypertension with established CV and renal diseases, the BP goal is \< 130/80. (According to 2007 European Society of Hypertension (ESH) - European Society of Cardiology (ESC) guideline)

  • Participant is either receiving antihypertensive therapy or no treatment.
  • Participants with stable diabetes mellitus may enter the study.

Exclusion criteria

Exclusion criteria:

  • Pregnant or lactating females.
  • Secondary hypertension of any etiology (such as unilateral or bilateral renal

disease, renal artery stenosis, coarctation of the aorta, pheochromocytoma).

  • History of malignant hypertension.
  • Sitting systolic blood pressure >210 mmHg at Visit 1 (Day 0).
  • Participants with unresolved cerebrovascular accident or in the acute stage at visit 1.
  • A clinically confirmed myocardial infarction within the recent 3 months.
  • Angina pectoris.
  • cardiac arrhythmia.
  • History of unexplained syncope within the prior 2 years, or a known syncopal

disorder.

  • Presence of hemodynamically significant obstructive valvular disease of

cardiomyopathy.

  • Percutaneous coronary angioplasty or coronary artery bypass surgery within the prior 3 months of visit 1.
  • Participant with a single functioning kidney.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Losartan 50 mg / HCTZ 12.5 mg

    Participants with mild to moderate essential hypertension who will receive Losartan 50 mg / HCTZ 12.5 mg once-a-day for 12 weeks.

    Drug: Losartan 50 mg / HCTZ 12.5 mg

Interventions

  • DrugLosartan 50 mg / HCTZ 12.5 mg

    Drug page: Losartan

    Losartan 50 mg / HCTZ 12.5 mg tablet once daily for 12 weeks

    Also known as: MK-0954A

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12

    Participants with SiDBP of 95-115 mmHg at the end of Baseline had SiDBP measured after 12 weeks of treatment.

    Time frame: At Baseline and Week 12

07

Results

Posted Nov 22, 2011

Participant flow

Participant flow — Overall Study
MilestoneLosartan 50 mg / HCTZ 12.5 mg
Started15
Completed13
Not completed2
Withdrew: Lack of efficacy1
Withdrew: Unable to follow protocol procedures1

Outcome measures

PrimaryMean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12

Participants with SiDBP of 95-115 mmHg at the end of Baseline had SiDBP measured after 12 weeks of treatment.

Time frame:
At Baseline and Week 12
Reported as:
Mean · mm Hg
Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12
mm HgLosartan 50 mg / HCTZ 12.5 mg
Baseline (N = 15)99.2 ± 5.5
Change from Baseline at Week 12 (N = 13)-12.7 ± 3.2
Statistical analysis
  • Losartan 50 mg / HCTZ 12.5 mg · t-test, 2 sided · p = <0.05

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Losartan 50 mg/HCTZ 12.5 mg—0/15 (0%)8/15 (53.3%)
Most frequent other events
Showing 10 of 13
Most frequent other events
EventLosartan 50 mg/HCTZ 12.5 mg
BLOOD URIC ACID INCREASEDInvestigations3/15
BLOOD GLUCOSE ABNORMALInvestigations2/15
BLOOD TRIGLYCERIDES INCREASEDInvestigations2/15
ARRHYTHMIACardiac disorders1/15
PALPITATIONSCardiac disorders1/15
ABDOMINAL DISTENSIONGastrointestinal disorders1/15
GASTRITISGastrointestinal disorders1/15
ASPARTATE AMINOTRANSFERASE INCREASEDInvestigations1/15
BLOOD CHOLESTEROL INCREASEDInvestigations1/15
BLOOD POTASSIUM DECREASEDInvestigations1/15

Baseline characteristics

Age, Continuous
Age, Continuous(years)Losartan 50 mg / HCTZ 12.5 mg
Mean50.5 ± 6.7
Sex: Female, Male
Sex: Female, Male(Participants)Losartan 50 mg / HCTZ 12.5 mg
Female6
Male9
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2007 to primary completion in Jun 2009, 22 months.

Results were first posted in Nov 2011, 2 years 5 months after primary completion.

Of 35 industry-sponsored phase 4 interventional studies under Hypertension, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 22 months is close to that.

Counting every sponsor, half of 161 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2011
First posted
Sep 9, 2011
StartActual
Aug 1, 2007
Primary completionActual
Jun 1, 2009
CompletionActual
Jun 1, 2009
Results first posted
Nov 22, 2011
Last update
May 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01431508
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Sep 9, 2011
Start date
Aug 1, 2007
Primary completion
Jun 1, 2009
Completion
Jun 1, 2009
Results posted
Nov 22, 2011
Last update
May 22, 2024

Study contacts

Du-Yi Lee, M.D.
principal investigator · Cheng Ching General Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Losartan

Start the discussion